Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
Background Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not all patients benefit from them, and tools that could be used in...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMJ Publishing Group
2025-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Acceso en liña: | https://jitc.bmj.com/content/13/1/e010059.full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|